Imagine standing in your bathroom, staring down at your current prescription bottles, terrified that your daily SSRI or SNRI might block the effects of your upcoming ketamine treatment. In Episode 62, we tackle "The Combination Question" by breaking down a highly practical 2026 brief report from Yale by Curran, Hardy, and colleagues.

Looking at real-world data from 332 patients with Treatment-Resistant Depression (TRD), researchers uncovered a "beautifully boring" but life-altering reality: there is absolutely no significant difference in ketamine's clinical success regardless of what background antidepressant class a patient is currently taking. We explore the neurobiology behind this phenomenon. Traditional oral antidepressants act like "traffic cops" trying to route signals efficiently on a broken, congested monoamine highway. Ketamine, however, bypasses that system entirely; it acts on the glutamate system to release BDNF, essentially deploying a "construction crew" to pave an entirely new, high-speed neural bypass. Because they operate on completely different biological tracks, they do not interfere with one another.

This data offers massive relief. It proves patients do not have to endure agonizing, dangerous drug tapers or risk a severe depressive crash just to clear their system before starting ketamine. Psychiatry is finally moving away from the exhausting merry-go-round of drug "swapping" and entering a much more compassionate era of "layering" treatments.

Reference

Curran, E., Hardy, M., Katz, R., Rhee, T. G., & Wilkinson, S. T. (2026). Concurrent SSRI, SNRI, or other antidepressant use not associated with differential outcomes in ketamine or esketamine treatment. The Journal of Clinical Psychiatry, 87(2), 25br16294. https://doi.org/10.4088/JCP.25br16294